A meta-analysis of 7 trials demonstrated that ACE inhibitors decrease overall mortality (OR, 0.86; 95% confidence interval, 0.79-0.93), myocardial infarction (OR, 0.82; 95% confidence interval, 0.75-0.89), cardiovascular mortality (OR, 0.81; 95% confidence interval, 0.73-0.90), and stroke (OR, 0.77; 95% confidence interval, 0.66-0.88) in patients with coronary artery disease and preserved left ventricular systolic function.